Company intelligence

APVO

Aptevo Therapeutics Inc. · NASDAQ · Healthcare

Price$1.84+0.00% · +$0.00

Market cap4.02MEquity value

P / E0.0Trailing ratio

Volume40.8KLatest session

Market data

APVO price chart

TradingView

Related signals

1 min delayed

Browse public APVO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

APVOSep 3, 2026-3.33% since signal

APVO's mipletamig triplet yields 93% benefit in TP53-mutant AML

Aptevo disclosed that mipletamig, used with venetoclax and azacitidine, achieved a 93% clinical benefit rate in frontline TP53-mutated AML. In 13 of 14 evaluable patients, 11 reached remission, including nine full CRs. The RAINIER program targets dose optimization by year-end with 2027 regulatory discussions, signaling a potential late-stage catalyst if efficacy persists.

View signal analysis

APVOJun 20, 2025-18.71% since signal

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Aptevo Therapeutics Inc. shares fell 11.9% to $4.52 in pre-market trading. The company experienced an 82% increase on Wednesday post-clinical data announcement. Market overall was lower, with Dow futures down 0.2% this morning. Other biotech stocks also showed declines during pre-market trading. Smith & Wesson's disappointing earnings report affected overall market sentiment.

View signal analysis

APVOJun 18, 2025-28.06% since signal

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

APVO stock surged 137.2% with high trading volume. New data from RAINIER trial shows 85% remission in AML patients. No CRS observed; mipletamig demonstrates strong safety profile. Direct offering of $8 million at $3.25 per share announced. Unique immunotherapy approach positions APVO favorably in AML market.

View signal analysis

Research